Literature DB >> 19138969

Development and validation of a lung cancer risk prediction model for African-Americans.

Carol J Etzel1, Sumesh Kachroo, Mei Liu, Anthony D'Amelio, Qiong Dong, Michele L Cote, Angela S Wenzlaff, Waun Ki Hong, Anthony J Greisinger, Ann G Schwartz, Margaret R Spitz.   

Abstract

Because existing risk prediction models for lung cancer were developed in white populations, they may not be appropriate for predicting risk among African-Americans. Therefore, a need exists to construct and validate a risk prediction model for lung cancer that is specific to African-Americans. We analyzed data from 491 African-Americans with lung cancer and 497 matched African-American controls to identify specific risks and incorporate them into a multivariable risk model for lung cancer and estimate the 5-year absolute risk of lung cancer. We performed internal and external validations of the risk model using data on additional cases and controls from the same ongoing multiracial/ethnic lung cancer case-control study from which the model-building data were obtained as well as data from two different lung cancer studies in metropolitan Detroit, respectively. We also compared our African-American model with our previously developed risk prediction model for whites. The final risk model included smoking-related variables [smoking status, pack-years smoked, age at smoking cessation (former smokers), and number of years since smoking cessation (former smokers)], self-reported physician diagnoses of chronic obstructive pulmonary disease or hay fever, and exposures to asbestos or wood dusts. Our risk prediction model for African-Americans exhibited good discrimination [75% (95% confidence interval, 0.67-0.82)] for our internal data and moderate discrimination [63% (95% confidence interval, 0.57-0.69)] for the external data group, which is an improvement over the Spitz model for white subjects. Existing lung cancer prediction models may not be appropriate for predicting risk for African-Americans because (a) they were developed using white populations, (b) level of risk is different for risk factors that African-American share with whites, and (c) unique group-specific risk factors exist for African-Americans. This study developed and validated a risk prediction model for lung cancer that is specific to African-Americans and thus more precise in predicting their risks. These findings highlight the importance of conducting further ethnic-specific analyses of disease risk.

Entities:  

Mesh:

Year:  2008        PMID: 19138969      PMCID: PMC2854402          DOI: 10.1158/1940-6207.CAPR-08-0082

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  42 in total

1.  Lung cancer and exposure to man-made vitreous fibers: results from a pooled case-control study in Germany.

Authors:  H Pohlabeln; K H Jöckel; I Brüske-Hohlfeld; M Möhner; W Ahrens; U Bolm-Audorff; R Arhelger; W Römer; L Kreienbrock; M Kreuzer; I Jahn; H E Wichmann
Journal:  Am J Ind Med       Date:  2000-05       Impact factor: 2.214

2.  Long man-made fibers and lung cancer risk.

Authors:  S H Moolgavkar; J Turim; R C Brown; E G Luebeck
Journal:  Regul Toxicol Pharmacol       Date:  2001-04       Impact factor: 3.271

3.  Mortality from six work-related cancers among African Americans and Latinos.

Authors:  D Loomis; M Schulz
Journal:  Am J Ind Med       Date:  2000-11       Impact factor: 2.214

4.  Small cell lung cancer in women: risk associated with smoking, prior respiratory disease, and occupation.

Authors:  K E Osann; J T Lowery; M J Schell
Journal:  Lung Cancer       Date:  2000-04       Impact factor: 5.705

5.  Lung cancer risk associated with exposure to man-made fibers.

Authors:  S H Moolgavkar; E G Luebeck; J Turim; R C Brown
Journal:  Drug Chem Toxicol       Date:  2000-02       Impact factor: 3.356

6.  Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention.

Authors:  G A Colditz; K A Atwood; K Emmons; R R Monson; W C Willett; D Trichopoulos; D J Hunter
Journal:  Cancer Causes Control       Date:  2000-07       Impact factor: 2.506

7.  Previous pulmonary diseases and risk of lung cancer in Gansu Province, China.

Authors:  A V Brenner; Z Wang; R A Kleinerman; L Wang; S Zhang; C Metayer; K Chen; S Lei; H Cui; J H Lubin
Journal:  Int J Epidemiol       Date:  2001-02       Impact factor: 7.196

8.  Variations in lung cancer risk among smokers.

Authors:  Peter B Bach; Michael W Kattan; Mark D Thornquist; Mark G Kris; Ramsey C Tate; Matt J Barnett; Lillian J Hsieh; Colin B Begg
Journal:  J Natl Cancer Inst       Date:  2003-03-19       Impact factor: 13.506

9.  Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk.

Authors:  Matthew B Schabath; Margaret R Spitz; George L Delclos; Gary B Gunn; Lawrence W Whitehead; Xifeng Wu
Journal:  Am J Ind Med       Date:  2002-07       Impact factor: 2.214

10.  The LLP risk model: an individual risk prediction model for lung cancer.

Authors:  A Cassidy; J P Myles; M van Tongeren; R D Page; T Liloglou; S W Duffy; J K Field
Journal:  Br J Cancer       Date:  2007-12-18       Impact factor: 7.640

View more
  49 in total

1.  Admixture mapping of lung cancer in 1812 African-Americans.

Authors:  Ann G Schwartz; Angela S Wenzlaff; Cathryn H Bock; Julie J Ruterbusch; Wei Chen; Michele L Cote; Amanda S Artis; Alison L Van Dyke; Susan J Land; Curtis C Harris; Sharon R Pine; Margaret R Spitz; Christopher I Amos; Albert M Levin; Paul M McKeigue
Journal:  Carcinogenesis       Date:  2010-11-29       Impact factor: 4.944

2.  Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial.

Authors:  Li-Shiun Chen; Timothy B Baker; J Philip Miller; Michael Bray; Nina Smock; Jingling Chen; Faith Stoneking; Robert C Culverhouse; Nancy L Saccone; Christopher I Amos; Robert M Carney; Douglas E Jorenby; Laura J Bierut
Journal:  Clin Pharmacol Ther       Date:  2020-08-04       Impact factor: 6.875

Review 3.  Screening for lung cancer using low-dose computed tomography: concerns about the application in low-risk individuals.

Authors:  Jiu-Wei Cui; Wei Li; Fu-Jun Han; Yu-Di Liu
Journal:  Transl Lung Cancer Res       Date:  2015-06

4.  Mentholated cigarettes and smoking-related cancers revisited: an ecologic examination.

Authors:  Geoffrey C Kabat; Nitin Shivappa; James R Hébert
Journal:  Regul Toxicol Pharmacol       Date:  2012-03-10       Impact factor: 3.271

5.  Smoking behavior and lung cancer in a biracial cohort: the Atherosclerosis Risk in Communities study.

Authors:  Anna E Prizment; Hiroshi Yatsuya; Pamela L Lutsey; Jay H Lubin; Mark Woodward; Aaron R Folsom; Rachel R Huxley
Journal:  Am J Prev Med       Date:  2014-06       Impact factor: 5.043

6.  Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.

Authors:  Michele L Cote; Wonsuk Yoo; Angela S Wenzlaff; Geoffrey M Prysak; Susan K Santer; Gina B Claeys; Alison L Van Dyke; Susan J Land; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2009-01-27       Impact factor: 4.944

7.  Role of selected genetic variants in lung cancer risk in African Americans.

Authors:  Margaret R Spitz; Christopher I Amos; Susan Land; Xifeng Wu; Qiong Dong; Angela S Wenzlaff; Ann G Schwartz
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

8.  Selection criteria for lung-cancer screening.

Authors:  Martin C Tammemägi; Hormuzd A Katki; William G Hocking; Timothy R Church; Neil Caporaso; Paul A Kvale; Anil K Chaturvedi; Gerard A Silvestri; Tom L Riley; John Commins; Christine D Berg
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

9.  Self-reported prior lung diseases as risk factors for non-small cell lung cancer in Mexican Americans.

Authors:  Michelle K McHugh; Matthew B Schabath; Chung-Han Ho; Mei Liu; Anthony M D'Amelio; Anthony J Greisinger; George L Delclos; Margaret R Spitz; Carol J Etzel
Journal:  J Immigr Minor Health       Date:  2013-10

Review 10.  Pharmacogenomics of platinum-based chemotherapy in NSCLC.

Authors:  Michelle A T Hildebrandt; Jian Gu; Xifeng Wu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-07       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.